A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder

J Clin Psychiatry. 1985 Mar;46(3 Pt 2):32-7.

Abstract

Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder. After a 1-week placebo washout, patients were randomly assigned to 5 weeks of treatment with fluoxetine or amitriptyline. Fluoxetine was found to have a therapeutic effect comparable to that of amitriptyline; however, the fluoxetine treatment group had a better Efficacy Index-Side Effects rating and a lower incidence of anticholinergic autonomic side effects. Four amitriptyline-treated patients had to discontinue the study because of serious side effects, while in the fluoxetine treatment group there were no terminations due to side effects. The amitriptyline-treated patients gained significantly more weight than the fluoxetine-treated patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Ambulatory Care*
  • Amitriptyline / adverse effects
  • Amitriptyline / blood
  • Amitriptyline / therapeutic use*
  • Anxiety / chemically induced
  • Body Weight / drug effects
  • Clinical Trials as Topic
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / psychology
  • Dizziness / chemically induced
  • Female
  • Fluoxetine / adverse effects
  • Fluoxetine / blood
  • Fluoxetine / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Patient Dropouts
  • Placebos
  • Propylamines / therapeutic use*
  • Psychiatric Status Rating Scales
  • Tremor / chemically induced
  • Xerostomia / chemically induced

Substances

  • Placebos
  • Propylamines
  • Fluoxetine
  • Amitriptyline